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Genotypes responsible for interindividual differences in ability to activate ordetoxify genotoxic agents
are recognized as biomarkers of susceptibility. Among the most studied genotypes are human
glutathione transferases. The relationship of genetic susceptibility to biomarkers of exposure and
effects was studied especially in relation to the genetic polymorphism of glutathione S-transferase
Ml (GSTM1). For this review papers reporting the effect of GSTM1 genotype on DNA adducts,
protein adducts, urine mutagenicity, Comet assay parameters, chromosomal aberrations, sister
chromatid exchanges (SCE), micronuclei, and hypoxanthine-guanine phosphoribosl transferase
mutations were assessed. Subjects in groups occupationally exposed to polycyclic aromatic
hydrocarbons, benzidine, pesticides, and 1,3-butadiene were included. As environmentally exposed
populations, autopsy donors, coal tar-treated patients, smokers, nonsmokers, mothers, postal
workers, and firefighters were followed. From all biomarkers the effect of GSTM1 and N-acetyl
transferase 2 was seen in coke oven workers on mutagenicity of urine and of glutathione
S-transferase Ti on the chromosomal aberrations in subjects from 1,3-butadiene monomer
production units. Effects of genotypes on DNA adducts were found from lung tissue of autopsy
donors and from placentas of mothers living in an air-polluted region. The GSTM1 genotype affected
mutagenicity of urine in sm6kers and subjects from polluted regions, protein adducts in smokers,
SCE in smokers and nonsmokers, and Comet assay parameters in postal workers. A review of all
studies on GSTM1 polymorphisms suggests that research probably has not reached the stage
where results can be interpreted to formulate preventive measures. The relationship between
genotypes and biomarkers of exposure and effects may provide an important guide to the risk
assessment of human exposure to mutagens and carcinogens. Environ Health Perspect
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abstracthtml
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Introduction
Epidemiologic studies have indicated tobacco smoke, and diet. Individual sus-
that most human cancers are originally ceptibility to cancer may result from sev-
caused by environmental exposure to eral host factors including differences in
genotoxic agents. According to Doll and metabolism, DNA repair, oncogene and
Peto (1), up to 80 to 90% of all cancers tumor-suppressor gene activation, and
are related to environmental factors, nutritional status (2).
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Groups ofpolycyclic aromatic hydro-
carbons (PAHs), aromatic amines, and
nitroso compounds are regarded as the
most important environmental carcinogens.
It is increasingly clear that genetic differ-
ences among individuals in the ability to
modulate metabolism ofthese carcinogens
may play a primary role in susceptibility
to environmentally induced diseases (3-7).
Genetic polymorphism exists for a num-
ber ofactivating enzymes (phase I, repre-
sented by cytochrome P450 enzymes) and
detoxifying enzymes (phase II). The rela-
tionship ofgenetic polymorphisms to car-
cinogenicity has been extensively studied
for phase I enzymes on cytochrome P450
lAl (CYPIAJ) and cytochrome P450 2D6
(CYP2D6) genes or phase II enzymes on
glutathione S-transferase MI (GSTMI) and
N-acetyl transferase 2 (NAT2) genes.
The knowledge of the genetic basis
for individual metabolic variation has
revealed new possibilities for studies focus-
ing on increased susceptibility to environ-
mental cancer (8). Individuals susceptible
to various environmental carcinogens and
mutagens could have greatly heightened
genotoxic responses to exposures that induce
little or no response in nonstisceptible
individuals (9).
Recently new knowledge about suscepti-
bility to environmental hazards was reviewed
at the 12th Meeting ofthe Scientific Group
on Methodologies for the Safety Evaluation
ofChemicals: Susceptibility to Environ-
mental Hazards (10). Several conclusions
and recommendations were formulated, two
ofwhich are ofparticular interest. First,
determination ofsusceptibility to chemicals
in the workplace and general environment is
becoming increasingly feasible through rapid
advances in biologic sciences, particularly
molecular biology. Parallel advances that
have occurred in epidemiology, ecology, tox-
icology, and related sciences have greatly
facilitated the understanding and measure-
ment ofsusceptibility. Second, increased
understanding ofthe pathways to chemical
and physical agents leading to susceptibility
ofindividuals, populations, and ecosystems
in general is useful in protecting human
health and the environment.
Olden (11) recently noted that "to
address this problem the NIEHS [National
Institute ofEnvironmental Health Sciences]
proposes to expand its molecular genetic
research to identify susceptibility genes for
environmentally induced diseases through a
newenvironmental genomeproject."
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Genotypes are responsible for interindi-
vidual differences in ability to activate or
detoxify genotoxic agents as biomarkers of
susceptibility. Genes of this type include
those for cytochrome P450 and other
enzymes that convert inactive carcinogens
or mutagens to their genotoxic forms and
those that conjugate and thereby detoxify
these reactive forms. Many ofthese genes
are polymorphic in human populations
and potentially explain many ofthe inter-
individual differences observed both in
genotoxic responses indicated bybiomarkers
and disease outcome.
Genetic Polymorphisms
of GSTM1
Among the most studied genotypes are
human glutathione S-transferases (GSTs).
GSTs are multigene families of enzymes
involved in the metabolism ofa wide range
ofelectrophilic compounds ofboth exoge-
nous and endogenous origin. GSTs gener-
ally are recognized as detoxifying enzymes
because oftheir ability to catalyze the con-
jugation of these compounds with glu-
tathione. Their primary function is thought
to be the detoxification of reactive elec-
trophiles (12), but GSTs via their glu-
tathione-dependent peroxidase activities
also have an important role in free-radical
scavenging, thus protecting the cell from
deleterious effects ofoxidative stress (13).
GSTs may also be involved in the activa-
tion process of some carcinogens such as
haloalkanes and haloalkenes (14).
Genetic susceptibility has been studied
especially in relation to various biomarkers
for genetic polymorphisms of GSTMI.
The expression of GSTMI is inherited as
autosomal dominant and between 40 and
60% ofmost populations express GSTMI
(15). It is believed that genetic polymor-
phism exhibited by GSTMI may be a fac-
tor in determining an individual's
susceptibility to the toxic effect ofvarious
xenobiotics. The high activity of GSTMI to
convert PAHs to epoxide metabolites is
believed to be particularly important (16).
It was therefore suggested that these isoen-
zymes could serve as genetic markers forsus-
ceptibility to certain forms of cancer
(17-23). Recently the glutathione S-trans-
ferase TI (GSTTJ) gene has been identified
(24-26). This gene produces an enzyme,
thus catalyzing detoxification of mono-
halomethanes. It is believed that homozy-
gote individuals for the GSTTI-null allele
will have altered cancer risk. Frequency of
the null allele is expected to be between 10
to 30%.
The GSTMI gene is one ofthe most
extensivelystudiedgenes related to metabolic
polymorphisms and cancer risk. Seidegard et
al. (27) first published the evidence that
GSTMI deficiency may constitute a risk
factor for development ofcarcinoma ofthe
lungs, especially in smokers. McWilliams et
al. (28) examined 12 case-control studies
(27,29-39) on GSTM1 status and lung
cancer risk (a total of 1593 cases and 2135
controls). The results ofthis meta-analysis
confirmed that GSTM1 deficiency is a mod-
erate risk factor for development oflung
cancer, with an odds ratio of 1.41. GSTMI
deficiency accounts for almost 17% oflung
cancer cases. Ryberg et al. (40) suggested the
simultaneous significance of GSTM1 and
glutathione S-transferase P1 (GSTPI) geno-
types forlung cancer. Genetic factors maybe
more pronounced among patients who con-
tract lung cancer at a younger age. The
higher risk in GSTMJ-null genotype smok-
ers possibly is attributable to relevant car-
cinogens in cigarette smoke that may
theoretically reach cellular DNA and form
carcinogenic DNAadducts.
Kawajiri et al. (41) reported an associa-
tion of smoking-induced lung cancer
susceptibility with CYPlAI and GSTMI
polymorphism with the p53 gene. In non-
small-cell lung cancer patients with a sus-
ceptible CYPIA] genotype they observed
a remarkably high risk of mutation of
the p53 gene when combined with the
GSTMJ-null genotype.
Analysis ofthe contemporary literature
on biomarkers ofsusceptibility, exposure,
and effects shows that the relationship ofthe
GSTM1 genotype to other biomarkers was
reported most frequently. Therefore for this
review we considered those papers studying
the effect ofthe GSTMI genotype. Ifother
genotypes were studied simultaneously with
the GSTM1 genotype, their effects were also
analyzed. Papers were divided according to
the exposure dose into two groups: occupa-
tional and environmental exposure.
Occupational Exposure to
Mutagens and Carcinogens
Table 1 summarizes the effect ofgenotypes
on biomarkers ofexposure and effects by
occupationally exposed groups.
The effect of genetic polymorphisms
for GSTMI and CYPIA] was first stud-
ied by Carstensen et al. (42) and Ichiba
et al. (43) in chimney sweeps in Sweden.
Occupational exposure to PAHs in this
group was judged to be relatively low. The
study of sweeps showed significantly
increased aromatic DNA adduct levels in
total white blood cells in workers with
noninducible CYPlAI genotype ml/ml
and with combined CYPJAI-ml/ml and
GSTMI-null genotypes (43). The effect of
these genotypes on micronuclei was not
observed (42,43).
Another group exposed to PAHswas bus
maintenance workers (garage workers
exposed to diesel exhaust and mechanics
exposed mainly to oils) (44). There was no
significant difference in the DNA adduct
levels or mutant frequencybyhypoxanthine-
guanine phosphoribosyl transferase (HPRT)
between GSTMJ-null and GSTMJ-positive
individuals or between the slow and rapid
acetylators. In slow acetylators lacking the
GSTM1 gene, significantly higher DNA
adduct levels were observed. The exposure
was dassified according to type ofjob: work-
ers highly exposed to diesel engine exhaust,
mechanics exposed mainly to engine and
lubricating oils, and others, which included
electricalworkers.
A similar scheme was used to determine
the effect of GSTMI and NAT2genotypes
on DNAadducts in Copenhagen bus drivers
(45). The study group consisted of bus
drivers driving in the center ofCopenhagen,
in suburban residential areas, and in rural
and dormitoryvillage settings. Exposure esti-
mated as the air benzo[a]pyrene (B[a]P)
concentrations in a busy street in Copen-
hagen was 3.9 ng B[a]P/m3 compared
with 0.09 to 0.5 ng B[a]PIm3 in rural
areas. No significant effects of GSTMI or
NAT2 on DNA adduct levels were
observed either individually or combined.
A nonsignificant trend was observed in
individuals with the GSTMJ-null geno-
type; they had higher DNA adduct levels
in all exposure groups. Nielsen et al. (45)
claimed that GSTMI function is less
important at low level exposure.
One ofthe groups believed to be most
heavily exposed to PAHs is foundry and
coke oven workers. Hemminki et al. (46)
analyzed aromatic DNA adducts in foundry
workers in relation to exposure, lifestyle,
and CYPIAI and GSTMI genotypes using
groups in which no personal exposure mon-
itoring was carried out. Occupational expo-
sure to PAHs was extrapolated for the
period 1991 to 1993 according to personal
monitoring in 1990 and the decrease of
production and reduced exposure to PAHs
by workplace engineering improvements.
Groups experiencing exposure to more than
5 ng/m3 B[a]P were classified as high-expo-
sure groups and those experiencing concen-
trations less than 5 ng/m3 B[a]P were
classified as low-exposure groups. [These
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Table 1. Effectofgenotypes on biomarkers of exposure and effects byoccupationally exposed groups.
Biomarkers
Group/ DNA
sample size Exposure Genotypes adductsa Urineb CA SCE MN HPRT Reference
Chimney sweeps
n=69 PAHs GSTM1 NE - - - NE -
CYP1A1 E - - - NE - (42,43)
Bus maintenance workers
n=47 PAHs GSTM1 NE - - - - NE (44)
NAT2 NE - - - - NE
Bus drivers
n=90 PAHs GSTM1 NE - - - - - (45)
NAT2 NE - - - - -
Foundry workers
n=85 PAHs GSTM1 NE - - - - - (46)
CYP1A1 NE - - - - -
Coke oven workers
n=46 PAHs GSTM1 - E - - - - (47)
NAT2 - E - - - -
n=23 PAHs GSTM1 NE - NE NE - - (48)
NAT2 NE - NE NE - -
n=69 PAHs GSTM1 NE - - - - - (49)
NAT2 NE - - - - -
Soldiers
n=22 PAHs GSTM1 NE - - - - - (50)
CYP1A1 NE - - - - -
Dye production, benzidine workers
n=30 Benzidine GSTM1 NE NE - - - - (51)
Floriculturists
n=23 Pesticides GSTM1 - - NE NE NE - (52)
n=30 GSTM1 - - NE NE NE - (53)
GSTT1 - - NE NE NE -
NAT2 - - NE NE NE -
Monomer production workers
n=40 1,3-Butadiene GSTT1 - - E (56)
n=53 GSTM1 - - NE NE NE - (57)
GSTT1 - - E NE NE
Abbreviations: CA, chromosome aberrations; E, significant effect of genotype on biomarker; NE, no effect of geno-
type on biomarker; MN, micronuclei in lymphocytes. TMBy32P-postlabeling or ELISA. bUrine mutagenicity.
PAH levels in Finland seem low; in fact
they almost correspond to the environmen-
tal exposure in the busy streets of
Copenhagen.] Neither GSTMI nor
CYPIAI genotypes affected the level of
DNA adducts determined by 32P-postla-
beling. GSTMI appeared to modify the
DNA adduct levels compared to individu-
als lacking this gene. The authors suggested
that the effect ofgenotypes in their study
should not be used as negative evidence
because exposure to PAHs was low.
Gabbani et al. (47) analyzed the effect
of GSTMI and NAT2 on urinary muta-
gens in coke oven workers. No data on
exposure were presented. They observed
the combined effect between genotypes
and smoking. Smokers with the genotype
combination GSTMI null/NAT2-ss (slow
acetylator) showed the highest frequency
of positive urine mutagenicity among all
subjects. Smokers with the slow acetylator
genotype showed a higher frequency of
positive urine samples than smokers with
fast acetylator genotypes. The results
suggest that coke oven workers who are
smokers and carrygenotypes unfavorable for
detoxification ofaromatic amines (NAT2-
ss) and PAHs (GSTM1 null) may have an
increased riskofdevelopingbladdercancer.
Binkovai et al. (48) studied coke-oven
workers by using personal monitors to eval-
uate PAH exposure and analyzing DNA
adducts by 32P-postlabeling, chromosomal
aberrations, sister chromatid exchange
(SCE), and GSTMJ and NAT2 polymor-
phism. Exposure to carcinogenic PAHs
ranged between 0.6 and 632 pg/m3. No
effect ofeither genotype was observed on
any biomarker. A similar scheme was used
by Costa et al. (49) to examine the influ-
ence of GSTMI and NAT2 genotypes on
association between DNA adducts and per-
sonal exposure to PAHs (up to 200 pg/m3).
Again no effect ofeither genotype on DNA
adductlevel was observed. These results sug-
gest that these detoxification enzymes have
less effect on the complex dose-response
relationship athigh exposure to PAHs.
Another group exposed to PAHs is U.S.
Army soldiers affected during the GulfWar
(50). Analysis of DNA adducts by 32p-
postlabeling and dissociation-enhanced lan-
thanide fluoroimmunoassay revealed no
observed association between any bio-
markerand GSTMJ or CYPIAJ genotypes.
The impact ofoccupational exposure to
benzidine in relation to the GSTMI geno-
type was studied in workers currently
exposed to benzidine (manufacturing benzi-
dine dihydrochloride and benzidine-based
dyes) by analyzing DNA adducts in the
urothelial cells and urinary mutagenicity
(51). The GSTMI genotype had no impact
on DNA adducts and urinary mutagenicity
levels in these exposed workers. The authors
concluded that the GSTMI-null genotype
does not have any impact on bladder cancer
caused bybenzidine exposure.
Scarpato et al. (52) studied the impact of
GSTM1, GSTTI, and NAT2genotypes on
chromosomal aberrations, SCEs, and
micronudei in floroculturists exposed to dif-
ferent types ofpesticides. The level ofcyto-
genetic damagewas not significantlyaffected
by the agrochemical exposure ofthe subjects
regardless of the level ofpesticide used.
GSTMI, GSTTI, and NAT2genotypes did
not influence thelevel ofcytogenetic damage
among floroculturists and control subjects.
Surprisingly, GSTMI-null individuals who
smoked hadhigherfrequencies ofchromoso-
mal aberrations than GSTMI-positive smok-
ers. NAT2 polymorphism could not be
related to anyspontaneous or induced differ-
ences in the cytogenetic parameters studied.
Later Scarpato et al. (53) increased the num-
ber ofgreenhouse workers in their study
from 23 to 30 subjects. GSTMJ-null smok-
ers had significantly increased chromatid-
type aberrations. The effect was more
pronounced in both GSTM1 and GSTTI-
null genotype individuals, which suggests
theirpossible interaction.
Wiencke et al. (54) worked out a
technique to identify subjects sensitive to
epoxide-induced damage. Peripheral lym-
phocytes of GSTM1-deficient and -nonde-
ficient individuals were treated with
trans-stilbene oxide. The GSTMI-null
genotype individuals were associated with a
significant increase of SCE. The results
indicated that GSTMI is also a marker of
susceptibility to the induction ofcytoge-
netic damage by a certain class ofmutagens.
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Later Pemble et al. (55) identified a null
allele at the GSTTJ locus. The same
approach was used by Kelsey et al. (56) to
identify in vitro sensitivity oflymphocytes
in GSTTI-null subjects to diepoxybutane.
Personal monitoring was also used in
studies analyzing the effect ofexposure to
1,3-butadiene. Kelsey et al. (56) observed
in workers exposed to approximately 0.5
mg/m3 1,3-butadiene that a proportional
population with the GSTTJ-null genotype
had lymphocytes with increased sensitivity
to diepoxybutane in vitro, determined as
SCE. Because diepoxybutane is one ofthe
1,3-butadiene metabolites, lack of a
GSTT1 gene was postulated to increase the
risk of 1,3-butadiene exposure. Later Sorsa
et al. (57) confirmed this idea on a larger
sample ofworkers exposed to a low level of
1,3-butadiene during monomer produc-
tion. The GSTM1 genotype had no effect
on chromosomal aberrations, SCE, and
micronuclei, but significantly increased lev-
els of chromosomal aberrations were
observed in workers lacking the GSTT1
gene. The doubling ofchromosomal aber-
ration rate among the workers lacking the
GSTT1 gene suggests the importance of
the GSTTJ gene in the detoxification
pathway of 1,3-butadiene in vivo. These
results formed the basis of an idea to use
GSTTI genotype determination for 1,3-
butadiene-exposed workers as part oftheir
preventive medical examinations before
they began work in monomer production
and polymerization units.
Environmental Exposure
to Mutagens
and Carcinogens
Table 2 summarizes the effect ofgenotypes
on biomarkers ofexposure and effects by
environmentally exposed populations.
The first study attempting to establish a
relationship between genotypes and DNA
adducts in parenchymal lung tissue
obtained from autopsy donors was that of
Shields et al. (58). Higher DNA adduct
levels were associated with the GSTMJ-
null genotype. No correlation was found
between PAH-DNA adducts and CYPIAI
exon 7 mutations. This study proved the
effect of the GSTMI-null genotype on
DNA adducts level detected by 32P-postla-
beling assay for bulky aromatic adducts.
Kato et al. (59) examined the effect
of GSTMI, CYPIAI, CYP2D6, and
cytochrome P450 2E1 (CYP2E1) geno-
types on DNA adducts in lung tissues
from autopsy donors. The GSTMI-null
genotype was associated with higher
Table 2. Effect ofgenotypes on biomarkers of exposure and effects by environmentally exposed populations.
Biomarkers
Group/ DNA Protein
sample size Genotypes adductsa adductsb Urinec Comet CA SCE MN HPRT Reference
Autopsy donors
n=38 GSTM1 E - - - - - - - (58)
CYP1A1 NE - - - - - - -
n=90 GSTM1 E - - - - - - - (59)
CYP2D6 E - - - - - - -
CYP2E1 E - - - - - - -
Patients, coal tar
n=57 GSTM1 NE NE - - - - - - (60)
Smokers
n=17 GSTM1 - - E - - - - - (61)
NAT2 - - NE - - - - -
n=63 GSTM1 NE - - - - - - - (62)
n=159 GSTM1 NE - - - - - - - (63)
CYP1A1 E - - - - - - -
n=156 GSTM1 - - - - E NE - (64)
n=21 GSTM1 NE - - - - - - - (65)
GSTP1 NE - - - - - - -
n=151 GSTM1 - E - - - _ _ _ (66)
Nonsmokers
n=120 GSTM1 NE NE - - - - - - (67)
n=76 GSTM1 - - - - - - - NE (68)
n=22 GSTM1 - - - - - E - NE (69-71)
n=38 GSTM1 - - - - - - NE - (72)
Mothers, blood
n=128 GSTM1 - NE - - - - - - (73)
n=74 GSTM1 - - - NE - - - - (74)
Mothers, placenta
n=98 GSTM1 E - - - - - - - (75)
Postal workers,
gardeners
n=65 GSTM1 NE NE E E NE NE - - (76)
Firefighters
n=47 GSTM1 NE - - - - - - - (77)
CYP1A1 NE - - - - - - -
Comet, Comet assay. &By 32P-postlabeling or ELISA. bProtein adducts, hemoglobin, or albumin adducts. cUrine
mutagenicity.
levels of PAH-derived DNA adducts,
CYP2D6, and CYP2E1 genotypes with
7-methyl-2'-deoxyguanosine-3-
monophosphate adduct levels in non-
smokers. These findings suggest that
genetic polymorphisms may predict car-
cinogen-DNA adduct levels and thus
might predict an individual's lifetime
response to carcinogen exposure.
Santella et al. (60) tried to determine if
the levels of DNA and protein adducts in
coal tar-treated psoriasis patients might be
affected by the GSTMJ genotype. DNA
adducts and PAH-albumin adducts were
determined by enzyme-linked immunosor-
bent assay (ELISA). DNA adducts but not
PAH-albumin adducts were elevated in
patients. However no relationship was
found between DNA or protein adduct
levels and the GSTMI genotype.
Most environmental studies have been
concerned with the effect of exposure to
tobacco smoke. One ofthe first papers was
by Hirvonen et al. (61), who examined the
effect of GSTM1 and NAT2 genotypes on
urinary mutagenicity using Salmonella
typhimurium tester strains TA98 and
YG1024. Smokers lacking the GSTMI gene
had several times higher urine mutagenicity
than smokers who had the gene. Such an
effect was not observed among nonsmokers.
No effect ofNAT2genotypes was detected
amongsmokers or nonsmokers.
Grinberg-Funes et al. (62) observed no
increase of DNA adducts determined by
competitive ELISA in GSTMI-null smok-
ers. When DNA adducts were stratified
according to GSTMI genotype and plasma
levels ofvitamins E and C in these individ-
uals, a relationship between DNA adduct
levels and the GSTMI genotype was
observed. This finding is consistent with
inverse associations between antioxidant
micronutrient status and the GSTMI
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genotype, which could modulate DNA
adduct formation.
Mooney et al. (63) analyzed the effect of
GSTM] and CYPJA] genotypes on DNA
adducts by competitive ELISA in heavy
smokers. No effect ofGSTM]-null genotype
was detected. DNA adducts were increased
in smokers with the CYPJAJ exon 7 valine
polymorphism. There was no apparent inter-
action between CYPJAJ and GSTM] geno-
types with respect to DNA adducts in the
smokers. A decreased level of1-carotene was
detected in GSTMJ-null genotype subjects.
Association between DNA adducts and 1-
carotene levels in smokers lacking the
GSTM] gene indicates that vitamin levels
may be more critical in persons who do not
have the ability to detoxify PAHs via the
GSTM] pathway than in other individuals.
The authors proposed that smokers with
either CYPIA] exon 7 polymorphism or low
levels ofmicronutrients alone or in combina-
tion with the GSTMI-null genotype sustain
more genetic damage from cigarette smoking
and other environmental exposures to PAHs
than individuals without these factors.
SCE in peripheral lymphocytes and
micronuclei in sputum cells were used as
biomarkers for increased cytogenetic dam-
age (64). SCEs were higher in smokers
with the GSTMl-deficient phenotype.
This effect ofphenotype was not observed
in micronuclei ofsputum cells.
Savela et al. (65) investigated DNA
adduct formation in bronchoalveolar
macrophages ofsmokers and nonsmokers
in relationship to GSTMI and GSTPI
genotypes. The number of cigarettes
smoked per day had a stronger influence on
DNA adducts than polymorphic genotypes.
Yu et al. (66) studied the effect ofthe
GSTM] genotype on 3- and 4-amino-
biphenyl (ABP) hemoglobin adduct levels in
white, black, and Asian smokers and non-
smokers. 4-ABP hemoglobin adducts were
significantly higher in subjects possessing
the GSTM]-null genotype.
Nielsen et al. (67) studied the impact of
exposure to urban and rural air pollution in
healthy male nonsmokers from Denmark
and Greece. No effect of GSTM] on DNA
and protein adduct level was observed, prob-
ablybecause ofthe lowlevel ofpollution.
Another group of healthy male
nonsmokers was followed in Stockholm
using HPRTT-cell cloning assay (68). The
difference in HPRTmutant frequency was
not significant between GSTM]-negative
and GSTM]-positive individuals. The
study showed that age contributes more
than GSTM] polymorphism to the large
interindividual variation in HPRTmutant
frequency ofnonsmokers.
Cheng et al. (69,70) observed the effect
ofthe GSTM] genotype on SCE frequercy
in nonsmokers; SCE frequency was higher
in subjects ofboth sexes lacking this gene.
A similar effect was not found in former or
current smokers. In the same group the
mutant frequency at the HPRTlocus (71)
and micronuclei in human lymphocytes
(72) were studied. Mutant frequency at
HPRTand micronuclei frequency were not
associated with GSTM] polymorphism.
Autrup et al. (73) determined the
transplacental transfer ofgenotoxic material
using a competitive ELISA assay to measure
PAH-albumin adduct level in serum iso-
lated from the mother and the umbilical
cord. Air pollution measured by suspended
particulate matter in the city ofAarhus,
Denmark, between 1988 and 1990 was esti-
mated on average to be 62 pg/m3. Protein
adducts were related in decreasing order to
rural areas, Aarhus, and suburban areas. The
GSTMI genotype did not significantly alter
the serum albumin adduct level.
The Comet assay, which determines
DNA single-strand breaks, was used to
evaluate the impact of air pollution in a
polluted region. The assay used whole
blood from mothers and umbilical cords
(58). No effect ofthe GSTM] genotype on
comet parameters (as a percentage ofDNA
in tail or tail length) was observed (74).
Topinka et al. (75) used human
placentas to study DNA adduct levels in
relation to the GSTM] genotype in moth-
ers living in two regions with different
average air pollution levels. Total DNA
adduct levels were significantly higher in
the polluted region and more pronounced
in winter. Higher DNA adduct levels were
detected in the group of mothers with the
GSTM1-null genotype. This finding seems
more relevant to subjects living in polluted
industrial areas.
An environmental study that used
personal monitoring ofcarcinogenic PAHs
in a group ofhealthy women who worked
outdoors was reported by Binkovai et al.
(76). The series of biomarkers included
PAH metabolites in urine, urine muta-
genicity, PAH-DNA adducts in white
blood cells determined by 32P-postlabeling,
PAH-albumin adducts determined by
ELISA, DNA damage in lymphocytes by
Comet assay, chromosomal aberrations,
SCE, and the GSTM] genotype. There
were no observed effects of the GSTM]
genotype on DNA and protein adduct
levels, chromosomal aberrations, or SCE.
Urinary PAH metabolites were significantly
increased in GSTM]-null genotype subjects
in the polluted district. In the Comet assay
there was a significant increase ofDNA per-
centage in tail and an increase of urinary
mutagenicity associated with the GSTM]-
null genotype, but the effect of personal
exposures to PAHs on the variability ofbio-
markers was more pronounced than the
effect of the GSTM] genotype. DNA
adducts tended to show an increase in the
GSTM]-null genotype.
In a group offirefighters (77) the level
ofPAH-DNA adducts measured by ELISA
in white blood cells was not significantly
related to GSTMI or CYPIA] genotypes.
However there was a positive association
between consuming charbroiled food and
PAH-DNA adduct formation. These
results suggest that the GSTMI-null geno-
type and CYPIA] exon 7 polymorphisms
are not associated with increased suscepti-
bility to PAH-DNA adduct formation in
peripheral white blood cells measured by
ELISA in nonsmoking populations.
Discussion
Literature on the effect ofgenotypes and
different sites of cancer is extensive.
However, only 34 recent papers were found
that study the effect of GSTMI together
with other genotypes on biomarkers of
exposure and of effects related to occupa-
tional or environmental exposure to muta-
gens and carcinogens. Using a well-known
paradigm of environmental cancer (78),
biomarkers for the entire spectrum of
human genotoxicant interactions begin with
exposure. Many papers lack data on air pol-
lution measured during the same period
that the blood samples were collected. With
regard to occupational studies, only four
papers (48,49,56,57) have been found that
compared biomarkers to personal exposures.
This may be one ofthe reasons epidemiolo-
gists usually acknowledge the limitations of
biomarkers in cancer epidemiology (79).
Validated biologic markers ofsuscepti-
bility can be used as effect modifiers in
epidemiologic studies. Interpretation of
effect modification depends on the statisti-
cal method (e.g., multiplicative or addi-
tive) used to model interaction. From the
biologic perspective effect modification
can explain why two similarly exposed
individuals may not both develop a dis-
ease. In part the answer is individual vari-
ability in metabolic, detoxification, and
repair capabilities (80).
Possession ofa susceptible gene should
decrease the biologically effective dose or
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elevate the risk ofdisease. Khoury et al. (81)
proposed six possible patterns of gene-
environment interaction to evaluate genetic
marker-disease associations and their interac-
tions with specific environmental riskfactors.
According to Rothman et al. (82), suscepti-
bility genes are common in the population,
are generally considered polymorphisms, and
mayinteractwith aparticular exposure.
Our review suggests that exposure to
carcinogens is usually affected by several
genotypes. It is possible that ifindividuals
lack a certain genotype, detoxification may
proceed through another pathway. There
are only a few studies that analyze the sig-
nificance of several genotypes simultane-
ously. New input is expected from the
environmental genome project (11).
It is difficult to decide how genetic
polymorphisms should be interpreted in risk
assessment. Until now there have been
only two studies on the effect ofgenotype
on human health. Rothman et al. (83)
evaluated the impact ofgenetic predisposi-
tions that activate (e.g., CYP2E1) and
detoxify reduced nicotinamide adenine
dinucleotide phosphate:quinone oxidore-
ductase (NQO1) benzene and its metabo-
lites. Occupational benzene poisoning is
associated with subsequent development of
acute nonlymphocytic leukemia and the
related myelodysplastic syndromes. The
authors showed that subjects homozygous
for the NQOI 609C-T mutation had a 7.6-
fold increased risk ofbenzene poisoning.
This is the first report providing evidence
that interindividual variation in metabolic
process among humans is associated with
the risk ofbenzene-associated disease. The
significance ofbenzene poisoning for hema-
tologic malignancy may be used to screen
new workers with benzene exposure for
NQOI polymorphisms. The Rothman et al.
study (83) suggests that in the future other
genotypes mayalso be found to be related to
specific types ofcarcinogen exposure.
Another example is GSTTJ polymor-
phisms for 1,3-butadiene occupational
exposure (57). The fact that subjects with
GSTTJ-null genotype have frequencies of
chromosomal aberrations twice as high as
GSTTI carriers means that GSTTI-null
genotype subjects will have higher risk of
malignancies (84,85). This agrees with
reports (84,85) showing that chromosomal
aberrations are increased before clinical
manifestation ofcancer.
At present the most sensitive biomarker
of exposure is thought to be identification
of DNA adducts by 32P-postlabeling
(86,87). However, no studies involving
high exposure to PAHs found any effects of
genotype on DNA adducts (Table 1).
Effects ofGSTM1 and NAT2were observed
in coke oven workers on mutagenicity of
urine (47) regardless ofbiomarker used;
these effects, however, were restricted to the
subgroup ofsmokers. Another effect was
observed with GSTTI genotype affecting
the frequency ofchromosomal aberrations
among workers from the 1,3-butadiene
monomer production unit.
In an analysis of environmentally
exposed populations, effects ofgenotypes on
DNA adducts from lung tissue ofautopsy
donors (58,59) and from placentas ofmoth-
ers living in an air-polluted region were
found (75). GSTMI-null genotype increased
the affected mutagenicity ofurine in smok-
ers (61) and in subjects from polluted
regions (76). A GSTMJ effect was also
observed from other biomarkers in smokers
on protein adducts (66) and SCE (64), in
nonsmokers on SCE (69), and in postal
workers on Comet assay parameters (76).
These results, however, appear too limited to
allow any significant conclusion. DNA
adducts were affected by GSTM1 in lung tis-
sue ofautopsydonors (58,59) and in placen-
tas ofmothers (75); tissues in both cases
correspond to thetarget tissue.
Vineis and Marton (88) speculated that
the effect ofgenotype is more pronounced
at low doses and that individual susceptibil-
ity is irrelevant under exceptionally high
exposure conditions. Ifone compares the
effects ofgenotypes on occupationally and
environmentally exposed populations in
Tables 1 and 2, their idea appears consistent
with the results ofthe reviewed studies.
Another important feature in epidemio-
logic studies may be an adaptive response,
as originallydemonstrated for ionizing radi-
ation (89). Coke oven workers are exposed
to high concentrations of PAHs but their
health risks do not correspond to the levels
ofcarcinogen exposure. Experience with
exposures in Eastern Europe indicates that
the impact ofpollution on human health is
less dramatic than the sum ofpollutants in
these regions (90,91). Similar unexpected
results were observed by Natarajan et al.
(92) among Indians inArgentina who were
exposed to high concentrations ofarsenic
but did not show any sign of chronic
arsenic poisoning. These examples suggest
an adaptive response in human popula-
tions-a response that surely is determined
bygenotype.
Our review covered several studies and
analyzed the effect ofgenotypes, especially
GSTMI, on biomarkers ofexposure and
effects for occupationally and environmen-
tally exposed populations. Considering all
studies with GSTMJ, we probably have not
reached the the stage where results could be
interpreted for preventive measures, e.g., to
predict risk because ofoccupational expo-
sure to mutagens and carcinogens, or to
identify hypersusceptible workers and
exclude them fromworking injobs inwhich
they may be exposed to high levels ofcar-
cinogens. The effect ofgenotypes was some-
times based on small sample size. For this
reason further studies should consider the
most suitable epidemiologic design for each
biomarker (82).
Conclusion
The impact ofgenetic polymorphisms as
biomarkers ofsusceptibility is ofkey signifi-
cance to the understanding ofthe process of
genetic damage involved in mutagenesis and
carcinogenesis. Studies published so far are
promising. The relationship between geno-
types, biomarkers ofexposure, and bio-
markers ofeffects could be important in risk
assessment ofhuman exposure to mutagens
and carcinogens.
Probably, at least for proved human
carcinogens, should be accepted: If the
genetic polymorphism ofgenes responsible
for detoxification pathways is known it is
reasonable to suggest that subjects lacking
these genes not be employed in occupa-
tions in which certain types ofexposure are
likely to occur.
Certain ethical questions must be
addressed ifknowledge about individual
genotypes is to be used to prescribe preven-
tive measures among specific groups. For
example, should the genotypes ofworkers
be identified as prerequisites to their work-
ing in environments with high exposures to
carcinogens such as PAHs in coke ovens? A
consensus must be reached about when
or where the use of new knowledge is
ethically acceptable.
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